1. Medtech Insight
  2. >>Business
  3. >>Financing

Syphilis OTC Test Developer NOWDiagnostics Raises $22.5M

 
• By Ryan Nelson

The Series B funding round led by DigitalDx Ventures will support development and commercialization of more than 30 rapid diagnostic tests in NOWDx’s clinical research pipeline, including its First To Know Syphilis OTC test, currently under US FDA De Novo review, which provides at-home results in minutes.

NOWDx entered a de novo classification request to the US FDA for its Syphilis OTC test in January. • Source: Shutterstock

NOWDiagnostics, Inc. aims to accelerate the development and commercialization of at-home diagnostic tests with $22.5m in series B funding, announced on 9 July.

The Springdale, AK-based company’s First To Know Syphilis OTC test is undergoing De Novo review by the US Food and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’

 
• By Marion Webb

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

Neuromodulation Tech Raises Billions Despite Commercial Uncertainty

 
• By Barnaby Pickering

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

HistoSonics Closed $250M Funding To Expand, But IPO ‘Not Immediate Priority,’ Says CEO

 
• By Marion Webb

The $250m in new funding from HistoSonics’ new owners and new investors Thiel Bio and Founders Fund will expand its histotripsy platform globally, advance new indications, and scale operations. CEO Mike Blue tells Medtech Insight that an IPO isn’t an immediate priority.

MedTech Innovator Winner Armor Medical Hopes To Reduce 90% Of Preventable Maternal Deaths

 
• By Marion Webb

Armor Medical’s wrist-worn wearable detected postpartum hemorrhage five times earlier than standard care in earlier studies. After surviving near-fatal hemorrhage herself, co-founder/CEO Kelsey Mayo aims to bring the device to market in 2028.

More from Business

Dexcom Targets Manufacturing Stability, 15-Day Rollout To Restore Margins In 2026

 
• By Shubham Singh

The 15-day sensor, which is initially being introduced within a limited “Warrior” community, will not meaningfully affect 2025 results but will begin to drive both margin expansion and access to lower reimbursement markets the following year.

Smaller Companies Next Frontier for FDA’s Voluntary Improvement Program

 
• By Elizabeth Orr

At the Medical Device Innovation Consortium summit, Cogmedix's Scott Cook discussed the challenges and benefits of transitioning to the FDA's Voluntary Improvement Program, which promotes honesty and opportunities for improvement, leading to faster market access and cost savings.

A Trillion On The Table. Addressing Disparities In Women’s Health Isn’t Just Right. It’s Smart.

 
• By Brian Bossetta

Advocates spanning the spectrum of women’s health met in Manhattan to discuss the gender disparities that remain in healthcare and how public policy can correct them and the enormous ROI investors in women’s health can potentially reap.